Sanofi Just Broke Up With the FDA's Fastest Review Program

Anonymous FDA sources told STAT News that it's extremely rare for a center director to intervene in an individual drug's scientific review. It's even more unusual when that director is a political appointee rather than a career scientist who came up through the ranks.

This is like the regional manager overruling the head chef on a recipe. You can do it, technically. But everyone in the kitchen notices.

The Irony Is Almost Too Perfect

Commissioner Makary himself has publicly stated he supports review teams and warned against political overrides causing "disaster." Yet the very program he created is now the one generating accusations of political meddling.

Sanofi's response has been carefully diplomatic. A spokesperson confirmed "confidential ongoing discussions" with the FDA but declined further comment. Reading between the lines: pulling out of the CNPV doesn't kill the application. Sanofi can still pursue approval through the standard review pathway. It just won't happen in two months.

The company's stock barely flinched, moving less than 1% on the news. Wall Street seems to view this as a procedural detour, not a dead end.

A Pattern, Not an Anomaly

This incident doesn't exist in a vacuum. Over the past year, the FDA has undergone what policy experts call an unprecedented overhaul. Nearly 90% of senior leaders from a year prior have been replaced. Political appointees now fill roles traditionally held by career staff. Scientific advisory committees have been terminated or restructured.

Richard Pazdur, a former FDA drug regulator with 26 years at the agency, put it bluntly: "Prior to this administration, I never really had a discussion with a commissioner about whether a drug should be approved."

Genevieve Kanter, a USC public policy professor, described the current situation as "unprecedented in terms of the depth and breadth" of politicization. She distinguished it from the first Trump administration, calling this an escalation.

Why This Matters Beyond One Drug

Tzield isn't a blockbuster. It treats a relatively small population of pre-diabetic patients at risk of developing type 1 diabetes. But the precedent here is enormous.

If political appointees can override career scientists on individual drug decisions, every company with a product in the FDA pipeline has to wonder: is my drug next? Will my review be decided by data, or by someone's agenda?

The CNPV program was already controversial before this. Eli Lilly and Novo Nordisk received vouchers ahead of a presidential press conference on drug pricing, suggesting coordination between the White House and FDA leadership. Some recipients reportedly hadn't even applied for vouchers. Criteria for selection remain opaque.

What Happens Next

Sanofi will likely pursue Tzield's expanded approval through conventional channels. Slower, yes, but potentially less politically fraught. The company already secured approval last month for an even broader indication (patients as young as 1 year old), so they know the data holds up.

The bigger question is whether the CNPV program can survive its own growing pains. A fast-track program only works if companies trust it. Right now, the first major test case ended with the applicant walking away.

That's not a great look for an express lane. Especially when the traffic jam was caused by the people running it.

No official response from HHS or the FDA has been issued. But in Washington, silence often speaks loudest. The pharmaceutical industry will be watching closely to see whether this was an isolated stumble or a preview of how drug regulation works now.

The FDA Just Killed the 60-Year-Old Way We Run Clinical Trials

The FDA is letting Amgen and AstraZeneca stream clinical trial data to regulators in real time, ditching the decades-old "run the study, then submit everything" model. If it works, drug development timelines could compress by months, and the entire industry will want in.